In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $84.00. The company’s shares closed last Tuesday at $37.25.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 8.1% and a 37.8% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals.
Arcturus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $72.50, representing a 94.9% upside. In a report issued on October 26, Barclays also initiated coverage with a Buy rating on the stock with a $72.00 price target.
Based on Arcturus Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.32 million and GAAP net loss of $10.26 million. In comparison, last year the company earned revenue of $10.15 million and had a GAAP net loss of $685K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.